Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

NCT04880577 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding

Conditions

Multiple Sclerosis, Relapsing-Remitting
Fatigue

Interventions

DRUG: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]
DRUG: Placebo

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]